$1,318.00
This Market Spotlight report covers the Amyloidosis market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, licensing and acquisition deals, and a 10-year disease incidence forecast, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Amyloidosis market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, licensing and acquisition deals, and a 10-year disease incidence forecast, as well as presenting drug-specific revenue forecasts.
Key Takeaways
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Subtypes
9 TREATMENT
9 Chemotherapy
9 Targeted therapy
9 Surgery
9 Bone marrow/stem cell transplantation
10 Palliative or supportive care
11 EPIDEMIOLOGY
11 Amyloidosis incidence methodology
12 Amyloidosis in multiple myeloma incidence methodology
15 TTR amyloidosis
17 MARKETED DRUGS
19 PIPELINE DRUGS
24 RECENT EVENTS AND ANALYST OPINION
24 AG10 for ATTR-CM, Wild Type Or Hereditary (December 27, 2021)
26 NTLA-2001 for hATTR Amyloidosis with Polyneuropathy (June 26, 2021)
28 Vutrisiran for hATTR Amyloidosis with Polyneuropathy (April 19, 2021)
30 Vutrisiran for hATTR Amyloidosis with Polyneuropathy (January 7, 2021)
33 KEY UPCOMING EVENTS
34 KEY REGULATORY EVENTS
34 Alnylam Picks Vutrisiran Extension Over CRL Risk
34 18-Month Data Build Case For Vutrisiran As It Awaits Approval
34 Alnylam’s Vutrisiran Among Myriad New Filings In EU
35 No To Five, Yes To Three: NICE Decides On Funding For Drugs In England
35 Alnylam’s Vutrisiran NDA Incorporates Earlier Onpattro Trial In hATTR Amyloidosis Patients
36 PROBABILITY OF SUCCESS
37 LICENSING AND ASSET ACQUISITION DEALS
37 AstraZeneca Doubles Down On Amyloidosis With Neurimmune Alliance
37 AstraZeneca Goes All In On AL Amyloidosis With Caelum Acquisition
37 Novo Nordisk Looks To Broaden Therapeutic Reach With Move Into ATTR
38 REVENUE OPPORTUNITY
40 CLINICAL TRIAL LANDSCAPE
41 Sponsors by status
42 Sponsors by phase
43 Recent events
47 BIBLIOGRAPHY
48 APPENDIX
LIST OF FIGURES
15 Figure 1: Trends in incident cases of primary amyloidosis in multiple myeloma, 2017–26
19 Figure 2: Overview of pipeline drugs for amyloidosis in the US
19 Figure 3: Pipeline drugs for amyloidosis, by company
20 Figure 4: Pipeline drugs for amyloidosis, by drug type
20 Figure 5: Pipeline drugs for amyloidosis, by classification
26 Figure 6: AG10 for ATTR-CM, Wild Type Or Hereditary (December 27, 2021): Phase III – ATTRibute-CM
28 Figure 7: NTLA-2001 for hATTR Amyloidosis with Polyneuropathy (June 26, 2021): Phase I – SAD (EU)
30 Figure 8: Vutrisiran for hATTR Amyloidosis with Polyneuropathy (April 19, 2021): Phase III – HELIOS A
32 Figure 9: Vutrisiran for hATTR Amyloidosis with Polyneuropathy (January 7, 2021): Phase III – HELIOS A
33 Figure 10: Key upcoming events in amyloidosis
36 Figure 11: Probability of success in the metabolic-other pipeline
40 Figure 12: Clinical trials in amyloidosis
40 Figure 13: Top 10 drugs for clinical trials in amyloidosis
41 Figure 14: Top 10 companies for clinical trials in amyloidosis
41 Figure 15: Trial locations in amyloidosis
42 Figure 16: Amyloidosis trials status
43 Figure 17: Amyloidosis trials sponsors, by phase
LIST OF TABLES
12 Table 1: Global incident cases of amyloidosis in adults, by type, 2017–26
14 Table 2: Global incident cases of primary amyloidosis in multiple myeloma, 2017–26
18 Table 3: Marketed drugs for amyloidosis
21 Table 4: Pipeline drugs for amyloidosis in the US
24 Table 5: AG10 for ATTR-CM, Wild Type Or Hereditary (December 27, 2021)
26 Table 6: NTLA-2001 for hATTR Amyloidosis with Polyneuropathy (June 26, 2021)
28 Table 7: Vutrisiran for hATTR Amyloidosis with Polyneuropathy (April 19, 2021)
30 Table 8: Vutrisiran for hATTR Amyloidosis with Polyneuropathy (January 7, 2021)
38 Table 9: Historical global sales, by drug ($m), 2017–21
39 Table 10: Forecasted global sales, by drug ($m), 2022–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!